Learn from Dr. Ron Vender and Dr. Sophia Colantonio about scalp dermatoses, here is a summary from their session:
Don’t feel like reading, listen to the podcast:
Managing scalp conditions is about much more than a bit of dandruff. In a recent Virtual Hallway webinar, dermatologists Dr. Ron Vender and Dr. Sophia Colantonio explored how common conditions like plaque psoriasis, seborrheic dermatitis, and atopic dermatitis profoundly impact patient quality of life. From the embarrassment of visible flakes to relentless itching and sleep disruption, these conditions carry a heavy burden. Here are the essential takeaways from their expert session and why you should catch the full recording.
The Burden of “High-Impact” Sites
Specialists are moving away from the term “hard-to-treat” areas, instead calling the scalp, face, and skin folds “high-impact sites.” These areas—including the hairline, eyelids, and genitals—significantly decrease a patient’s Quality of Life (DLQI) and are often associated with anxiety and depression. Notably, while many clinicians once believed psoriasis was not itchy, Dr. Vender emphasized that a majority of patients report significant pruritus.
Diagnosis: Silvery vs. Yellow Scale
The lecture provided visual keys to differentiate between common scalp conditions:
- Plaque Psoriasis: Features well-defined, erythematous plaques with a characteristic silvery scale. It often involves bony prominences like elbows and knees.
- Seborrheic Dermatitis: Known as the “milder cousin” of psoriasis, it typically presents with an ill-defined, yellow, greasy scale in oil-rich areas like the nasolabial folds and ears.
- Atopic Dermatitis: Known as “the itch that rashes,” its distribution changes with age, moving from extensor surfaces in infants to flexural predominance (like the neck and wrists) in adults.
When the diagnosis is unclear, the experts suggest using the term “sebopsoriasis” for the middle ground where features overlap.
Topicals: A Shift Toward Steroid-Free Control
While topical steroids remain a staple, the speakers warned against long-term use due to risks like skin atrophy, permanent striae (stretch marks), and systemic absorption. Primary care providers now have access to an expanding “toolbox” of non-steroidal options:
- Calcineurin inhibitors (tacrolimus, pimecrolimus): Useful for atopic dermatitis but often used off-label for psoriasis.
- PDE4 inhibitors: This class now includes Roflumilast (Zoryve), a once-daily topical that is Head-to-Toe safe.
- Aryl hydrocarbon receptor agonists: Newer agents like tapinarof cream offer high efficacy but may be limited by side effects like folliculitis.
Clinical Pearls for the Primary Care Physician
- Vehicle is King: For scalp treatment, foam is superior to creams or ointments as it is non-greasy and spreads easily through hair.
- Roflumilast (Zoryve) Foam: Now Health Canada-approved for both psoriasis (ages 12+) and seborrheic dermatitis (ages 9+). It is once-daily, non-steroidal, and should be applied to a dry scalp for best results.
- Safety First: Non-steroidal agents are preferred for maintenance therapy in chronic conditions to avoid the side effects of prolonged steroid use.
The Takeaway
The landscape for treating scalp dermatoses has evolved. With the arrival of once-daily, steroid-free foams that work across multiple conditions, primary care physicians can now offer safer, more convenient long-term management.
Watch the Full Lecture
Ready to master these diagnostic and treatment nuances? Watch the full session with Dr. Vender and Dr. Colantonio on Virtual Hallway to:
- Review visual case studies and differential diagnoses.
- Earn MainPro+ credits
- Sign up for free at virtualhallway.ca
Stay at the forefront of dermatology. Log in, learn, and help your patients achieve clearer skin and a better quality of life.